RedHill Biopharma Ltd (RDHL)

[midastouch017]

$26.72 Million in Sales Expected for RedHill Biopharma Ltd. (NASDAQ:RDHL) This Quarter

https://www.marketbeat.com/instant-alerts/nasdaq-rdhl-consensus-analyst-rating-2021-02/

SATURDAY, FEBRUARY 13, 2021 | MARKETBEAT

RedHill Biopharma logoEquities research analysts expect that RedHill Biopharma Ltd. (NASDAQ:RDHL) will announce sales of $26.72 million for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for RedHill Biopharma's earnings, with estimates ranging from $23.71 million to $29.73 million. RedHill Biopharma reported sales of $1.59 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 1,580.5%. The firm is expected to report its next quarterly earnings results on Wednesday, March 3rd.

On average, analysts expect that RedHill Biopharma will report full year sales of $68.05 million for the current fiscal year, with estimates ranging from $64.90 million to $72.63 million. For the next fiscal year, analysts anticipate that the business will post sales of $139.99 million, with estimates ranging from $114.21 million to $172.56 million. Zacks' sales averages are an average based on a survey of sell-side research firms that cover RedHill Biopharma.

RedHill Biopharma (NASDAQ:RDHL) last posted its quarterly earnings data on Tuesday, November 17th. The biotechnology company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.28). RedHill Biopharma had a negative return on equity of 152.19% and a negative net margin of 142.81%. The firm had revenue of $20.94 million for the quarter, compared to the consensus estimate of $23.57 million.

A number of research analysts recently commented on RDHL shares. Roth Capital decreased their price target on RedHill Biopharma from $16.00 to $12.00 and set a "buy" rating on the stock in a research report on Thursday, November 12th. Zacks Investment Research cut RedHill Biopharma from a "hold" rating to a "sell" rating in a research report on Wednesday, January 13th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company's stock. RedHill Biopharma presently has a consensus rating of "Buy" and an average price target of $15.75.